Simple Home Systems Help Reduce Everyday Stress

Newsrooms launch Signal Desk to curb health misinformation


Reviewing Medications at Home for Safety
Waikato Homes Tackle Dampness, Stale Air with Multi-Pronged Approach
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

Breast cancer drug Etcamah fails first-line trial test
Microbiome Diversity
Microbiome Diversity
Microbiome Diversity
Microbiome Diversity 


Group finds Trump drug deals favor drugmakers over patients
Public Citizen scrutinizes the Most-Favoured Nation pricing deals between the Trump administration and 27 pharmaceutical companies, arguing claims...
Three biotech firms eye Nasdaq listings
Three biotech firms—including ADARx Pharma—are preparing Nasdaq listings, with ADARx targeting a $1.74 billion valuation for its hereditary...
Bayer Moves Hyrnuo Into Frontline Lung Cancer
Bayer secured FDA approval for Hyrnuo lung cancer treatment, marking a major shift in frontline HER2-mutant NSCLC care...
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
Editor's picks
Why Is Medicaid Member Engagement Essential for Health
Medicaid is a cornerstone of healthcare access for millions of Americans, including low-income families, seniors, and individuals with disabilities. While...
Pharma struggles as AI fraud erodes patient trust in calls
AI fraud is eroding patient trust in pharma calls, with scammers using voice cloning and spoofing to mimic legitimate pharmaceutical...
NZ health planners adopt privacy-focused geospatial guidelines
New Zealand health planners are adopting privacy-focused geospatial guidelines to map immunisation rates and service usage while safeguarding location data.
New Zealand expands social prescribing with nine pathways
New Zealand expands social prescribing with nine pathways to address mental health, loneliness, and cost-of-living pressures through community resources.
NZ health planners adopt privacy-focused geospatial guidelines
New Zealand expands social prescribing with nine pathways
Pharma struggles as AI fraud erodes patient trust in calls
ESC 2026 AstraZeneca oral relaxin passes Phase II
All Post
Newsrooms Adopt “Slow News” to Boost Trust, Reduce Burnout
Newsrooms are rethinking their approach to breaking news, shifting towards a strategy known as "slow news." This method prioritizes verification, context,.
Group finds Trump drug deals favor drugmakers over patients
Public Citizen scrutinizes the Most-Favoured Nation pricing deals between the Trump administration and 27 pharmaceutical companies, arguing claims about savings
Three biotech firms eye Nasdaq listings
Three biotech firms—including ADARx Pharma—are preparing Nasdaq listings, with ADARx targeting a $1.74 billion valuation for its hereditary angioedema therapy.
Biotech and Digital Health Firms Expand Boards
Board appointments are reshaping biotech and digital health firms as August brings seasoned executives and scientific leaders onto boards to drive growth.
UK drug firms pull out of NICE reviews at record
UK drug firms are pulling out of NICE reviews at record levels in 2026, raising questions about industry shifts or systemic issues in the appraisal process.
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
The FDA has approved the first gene therapy, Fayuvi, for Sanfilippo syndrome type A, offering hope to affected children.
FDA Pilot Aims to Accelerate U.S. Drug Trials
The FDA's new pilot program aims to accelerate U.S. drug trials, reducing time from discovery to first-in-human studies.
Pharma struggles as AI fraud erodes patient trust in calls
AI fraud is eroding patient trust in pharma calls, with scammers using voice cloning and spoofing to mimic legitimate pharmaceutical outreach.
Breast cancer drug Etcamah fails first-line trial test
AstraZeneca’s breast cancer drug Etcamah failed its first-line trial, SERENA-4, raising doubts about its potential as a frontline treatment for HR-positive pati
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
Novo Nordisk drops its full name to become 'Novo,' sharpening focus against Eli Lilly in weight loss and diabetes treatments amid slowing growth.